MHRA clears Akantior
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) from Avanzanite Bioscience to treat acanthamoeba keratitis.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) from Avanzanite Bioscience to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ‘window’ at the front of the eye, that can be very painful. This medicine has been approved through the International Recognition Procedure (IRP). The IRP allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners for the benefit of UK patients.
Polihexanide is administered as an eye drop solution, directly into the eye. The MHRA conducts a targeted assessment of IRP applications and retains the authority to reject applications if the evidence provided is not considered sufficiently robust.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.